Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 19, Issue 10, 1997, Pages 989-999

  Dermime, S ^a   Mavroudis, D ^a   Jiang, Y Z ^a   Hensel, N ^a   Molldrem, J ^a   Barrett, A J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

AML; BMT; CML; GVL; Immune escape; Relapse

Indexed keywords

B7 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLONE; CYTOLYSIS; DONOR; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0030998834     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700778     Document Type: Article

References (30)

1. Apperley JF, Jones L, Hale G, Goldman GM. Bone marrow transplantation for chronic myelogenous leukaemia: T-cell depletion with Campath-1 reduces the incidence of acute graft-versus-host disease but may increase the risk of leukaemia relapse. Bone Marrow Transplant 1986; 1: 53-66.
2. Weiden PL, Horowitz MM. Graft-vs-leukaemia effects clinical bone marrow transplantation. In: Burakoff HJ, Deeg HJ, Ferrara I, Atkinson K (eds). Graft-vs-Host Disease; Immunology, Pathophysiology, and Treatment. Dekker: New York, NY, 1990, pp 691-708.
3. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Horowitz MM, Truitt RL. Graft-versus-leukaemia effects of bone marrow transplantation. In: Atkinson K (ed). Clinical Bone Marrow Transplantation. Cambridge University Press: Cambridge, 1994, pp 704-714.
5. Barrett AJ, Malkovska V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754-761.
6. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent CML in marrow transplant patients. Blood 1990; 76: 2462-2465.
7. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78: 2120-2130.
8. Antin JH. Graft-versus-leukaemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
9. Truitt RL, Johnson BD. Principles of graft-vs-leukaemia reactivity. Biol Blood Marrow Transplant 1995; 1: 61-68.
10. Bosslet K, Schirrmacher V. Escape of metastasizing clonal tumor cell variants from tumor specific cytolytic T lymphocytes. J Exp Med 1981; 154: 557-562.
11. Gronberg A, Kiessling R, Eriksson E, Hansson M. Variants from a MLV-induced lymphoma selected for decreased sensitivity to NK. J Immunol 1981; 127: 1734-1739.
12. Sondel PM, Hank JA, Molanda J et al. Relapse of host leukaemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the graft-versus-leukaemia effect. Exp Hematol 1985; 13: 782-790.
13. Taylor GM, Fergusson W, Dyer PA et al. An HLA-DR negative acute leukaemia which stimulates MLC and CMC responses. Cancer Immunol Immunother 1983; 16: 117-122.
14. Doyle A, Martin WJ, Funa K et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985; 161: 1135-1151.
15. Lassam N, Jay G. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol 1989; 143: 3792-3797.
16. Ferrone S, Marincola F, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-494.
17. Boon T, DePlaen E, Lurquin C et al. Identification of tumor rejection antigens recognized by T lymphocytes. Cancer Surv 1992; 13: 23-37.
18. Alexander M, Bennicelli J, Guerry D. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early disease. J Immunol 1989; 142: 4070-4078.
19. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
20. Trojan J, Johnson TR, Rudin SD et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing anti-sense insulin-like growth factor I RNA. Science 1993; 259: 94-97.
21. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
22. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
23. Matulonis UA, Dosiou C, Lamont C et al. Role of B7-1 in mediating an immune response to myeloid leukaemia cells. Blood 1995; 85: 2507-2515.
24. Jonjic N, Alberti S, Bernasconi S et al. Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. Eur J Immunol 1992; 22: 2255-2260.
25. Anichini A, Mortarini R, Alberti S et al. T cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int J Cancer 1993; 53: 994-1001.
26. Panayiotidis P, Ganeshaguru L, Foroni L, Hoffbrand AV. Expression and function of the Fas antigen in B chronic lymphocytic leukaemia and hairy cell leukaemia. Leukemia 1995; 9: 1227-1232.
27. Munker R, Lubbert M, Yonehara S et al. Expression of the Fas antigen on primary human leukaemia cells. Ann Hematol 1995; 70: 15-17.
28. Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17: 793-799.
29. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996; 93: 606-612.
30. Hayashi H, Tanaka K, Jay F et al. Modulation of the tumorigenicity of human adenovirus-12-transformed cells by interferon. Cell 1985; 43: 263-267.